Articles tagged with Hormone Therapy
A recent study found that low-dose estrogen treatment can stop disease progression in patients with metastatic breast cancer, with 87% of those without PET flare reactions showing no response. The treatment was also well-tolerated, with fewer severe side effects compared to high doses.
A new study found that denosumab significantly increased bone density at all monitored sites and reduced new vertebral fractures by 62% in men receiving androgen-deprivation therapy for prostate cancer. The treatment also showed improvements in bone density at the radius, one of the bones in the forearm.
A two-week course of erythropoietin injections has shown promising results in preventing brain damage in oxygen-deprived newborns. The treatment, which can be started up to two days after birth, improves the prognosis and reduces side effects compared to cooling.
Oral sodium clodronate reduces death by 23% and increases overall survival to 30% at 5 years for patients with advanced prostate cancer. However, in men with localized disease, clodronate shows no improvement in overall survival.
Studies found that botanicals were safe, but did not have a significant effect on reducing hot flashes or improving cognitive function compared to hormone therapy. The studies enrolled over 150 women and followed them for 12 months.
A new study by Louis Potters and colleagues found that permanent prostate brachytherapy is an effective treatment option for younger patients diagnosed with prostate cancer, with success rates comparable to older patients. The study analyzed data from 2,119 patients and showed that age didn't impact the long-term therapeutic outcome of...
Researchers at Northwestern University use nanodiamonds to deliver insulin for wound healing, demonstrating a method for localized release of therapeutic proteins. The nanodiamond-insulin clusters show promise for wound-healing applications and could be integrated into various treatments.
Researchers at Thomas Jefferson University identified DACH1 as a protein that prevents cancer cell proliferation by repressing estrogen receptors in ER+ breast cancer. As DACH1 expression decreases in breast cancer, estrogen receptor presence increases, suggesting its potential as a therapeutic target.
Women taking hormone therapy have a 38% increased risk of ovarian cancer, with risks increasing by 44% for epithelial tumors. The absolute risk is approximately 1 extra ovarian cancer for every 8,300 women taking hormone therapy annually.
Researchers found that curcumin delays tumor development and reduces multiplicity of progestin-accelerated tumors. Curcumin inhibits VEGF secretion from breast cancer cells, potentially reducing breast cancer risk for women exposed to hormone replacement therapy.
Sexual medicine experts focus on treating causes of sexual dysfunction beyond physical issues, exploring relationship dynamics and hormonal imbalance. New treatments and options for women and men are being developed to address complex sexual health needs.
Researchers discovered a potential new treatment for muscle atrophy, a debilitating condition characterized by loss of muscle mass and function. Des-acyl ghrelin, an appetite-stimulating hormone, shows anti-atrophic activity on skeletal muscle in mice with muscular atrophy.
A new study suggests that natural hormone angiotensin 1-7 may help treat the metabolic syndrome, a cluster of risk factors increasing heart disease and diabetes risk. Angiotensin 1-7 lowered fasting insulin levels and improved triglycerides and blood sugar in fructose-fed rats.
A new study found that hormone therapy combined with physical activity significantly reduces belly fat and body fat percentage in postmenopausal women. The research, which included 34 healthy women, showed that active women had lower waist measurements and better cholesterol levels after 4 months of hormone replacement therapy.
A recent study found that hormone therapy can alter prostate tumor properties, making them more aggressive and prone to metastasis. The treatment reduces male sex hormone production, but also increases levels of proteins enabling cancer cells to spread.
Versartis has presented positive preclinical data on its two product candidates, VRS-317 and VRS-826, which have the potential to extend half-life of drugs. The company's compounds have shown in vivo potency equal to daily hGH and sustained plasma levels without toxicity.
Researchers discovered that a nicotine receptor inhibitor, α-CbT, can double survival time in non-small cell lung carcinoma mice. The treatment showed significant antitumor activity by inducing apoptosis and had limited toxic effects on unaffected cells.
A new study found that taking a short break from postmenopausal hormone therapy does not lower the risk of false-positive mammogram results. However, it may help reduce breast density, making tumors harder to detect on X-rays.
Researchers used PET scanning to assess estrogen receptor positive breast cancer patients' response to standard aromatase inhibitor therapy after just two weeks. The results showed significant declines in glucose analogue FDG values, similar to earlier studies using needle biopsies.
A new study reveals that nearly one in four African American women with late-stage breast cancer refuse chemotherapy and radiation therapy. The authors emphasize the need for improved healthcare access and education to encourage treatment adherence. Further research is necessary to understand the factors contributing to this disparity.
A recent study published in Epidemiology found that hormone replacement therapy does not increase breast cancer risk for women with or without a family history. The research analyzed data from the Women's Health Initiative randomized trial and suggests that estrogen sensitivity may not be the causal pathway based on family history.
A study by Duke University Medical Center found that only 64% of low-income women with hormone receptor-positive breast cancer filled any prescriptions for hormonal therapy within 12 months after diagnosis. The researchers also discovered that 40% of the women stopped taking their medication regularly, and 20% stopped using it altogether.
A proteomic analysis of 50 participants from the Women's Health Initiative hormone replacement therapy trial reveals estrogen upregulates proteins involved in major body processes. The study found changes in serum levels of proteins affecting coagulation, metabolism, osteogenesis, and blood vessel morphogenesis.
A new analysis finds that prostate cancer patients who undergo testosterone-lowering therapy are at higher risk of bone fractures and heart-related deaths. The study highlights the need for preventive measures and careful health scrutiny to mitigate these risks.
A large study found that hormone therapy use was associated with a 28% lower incidence rate of colorectal cancer in older women. However, the mechanisms behind this protective effect are still unclear. The study also found no associations between hormone use and specific molecular markers or DNA methylation patterns.
Early diagnosis and treatment of achondroplasia's manifestations can produce better outcomes for patients later in life. This includes addressing stenosis of the foramen magnum and thoracolumbar kyphosis, which can cause developmental delays and spinal deformities.
A new study published in Menopause: The Journal of the North American Menopause Society found that transdermal estrogen delivery may not increase the risk of blood clots in postmenopausal women, unlike oral delivery. The study suggests that transdermal HT delivery may be a safer alternative for some women.
Researchers are developing new classes of anti-androgen therapies, including MDV3100, abiraterone, and OGX-427, to treat castrate-resistant prostate cancer (CRPC). Angiogenesis inhibitors like bevacizumab target vascular endothelial growth factor (VEGF) to slow tumor growth and metastasis.
New research suggests kisspeptin can activate release of sex hormones in women with infertility, leading to increased luteinising hormone production. The study found a 48-fold increase in LH and 16-fold increase in FSH in women treated with kisspeptin compared to controls.
Researchers found that estrogen activates genes encoding nitric oxide synthases, leading to enhanced lung function and reduced ventilation support needs. Estrogen also prevented low blood pressure and closed the ductus arteriosus, a shunt that connects the pulmonary artery to the aorta.
A study published in Journal of Psychopharmacology found that MDMA, a pharmaceutical version of Ecstasy, can enhance the effectiveness of exposure therapy for PTSD. By increasing oxytocin levels and reducing fear responses, ecstasy may help patients overcome traumatic memories and reduce stress.
Researchers used a six-gene model to stratify patients with castration-resistant prostate cancer, predicting survival and accuracy rates. The study found the model accurate in predicting low-risk patients' survival and high-risk patients' mortality.
A new study found that women with a longer fertile lifespan and more years of exposure to their own sex hormones may be protected from Parkinson's disease. Women with four or more pregnancies were at greater risk of developing the disease compared to those with fewer pregnancies.
A new study found that women with a longer fertile lifespan, resulting in higher levels of naturally produced estrogen, had a lower risk of developing Parkinson's disease. However, hormone therapy did not offer protection against the disease, and may even have harmful neurological effects.
A new study by Stanford researchers finds that combined estrogen plus progestin hormone therapy increases the annual risk of breast cancer in postmenopausal women, with a doubling of risk after five years. Stopping hormone therapy can quickly reduce this risk, as observed in a follow-up study.
Primary ovarian insufficiency is a menopause-like condition affecting girls and young women, characterized by loss of menstrual periods, infertility, and hot flashes. A comprehensive plan provides recommendations for diagnosis and treatment, including hormone replacement therapy and counseling.
A new study published in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that growth hormone treatment after weight loss surgery reduces lean body mass and skeletal muscle mass losses. Researchers discovered that short-term growth hormone treatment during a standardized diet and exercise program increased l...
A study published in JAMA found that using N-terminal brain natriuretic peptide (BNP) to guide therapy did not improve overall clinical or quality of life outcomes for older patients with heart failure. In contrast, the study showed improved survival rates and reduced hospitalizations for patients receiving BNP-guided therapy.
A Canadian/U.S. research team has reported a therapeutic model exploiting the natural dynamics of the 'fight or flight' system to stimulate recovery from chronic stress disorders. The HPA axis dysfunction may become chronic if driven far from its natural homeostatic rest point, leading to disorders like CFS, depression, and PTSD.
Key epigenetic abnormalities in endometriosis have been identified, including the presence of aromatase, which produces excessive estrogen in affected tissue. Aromatase inhibitors are now being tested for treatment options.
Experts warn that while hormonal contraceptives may be safe for many women, gaps in knowledge remain. The article highlights the need for further research on low-dose oral contraceptives and alternative forms of contraception for high-risk individuals.
New studies have found a link between hormone therapy and brain shrinkage in postmenopausal women, with smaller brain volumes in areas involved in thinking and memory skills. However, hormone therapy was not linked to an increase in small vascular lesions or 'silent strokes' that are often the first sign of cerebrovascular disease.
Two new studies link hormone therapy to reduced brain volume in critical memory areas, accelerating loss of cognitive function in postmenopausal women. Researchers found no correlation between hormone therapy and increased brain lesions, contradicting previous hypotheses.
Researchers have discovered a key difference in hormone receptors on prostate cancer cells in patients who no longer respond to hormone deprivation therapy. The finding, published in Cancer Research, could lead to new targets for treating prostate cancer and monitoring disease progression.
In a phase III trial, combining endocrine treatment with radiotherapy reduced prostate cancer mortality by half compared to endocrine treatment alone. The study found significant superiority of the combined treatment over hormone therapy alone in reducing prostate cancer-specific mortality and overall survival.
Studies show hormone supplements, such as estrogen-progestin and letrozole, can reduce breast cancer mortality risk by up to 63% and improve overall survival. Meanwhile, tamoxifen is found to be superior for quality of life measures, with patients paying a price in quality of life when switching from anastrozole.
A study of over 140,000 babies found late preterm births are associated with increased risk of cerebral palsy and mental retardation. The research highlights the need for early neurological assessments and cautious approach to elective deliveries before 39 weeks.
A study found that estrogen therapy can stop the growth of tumors or cause them to shrink in about a third of women with metastatic breast cancer that has developed resistance to standard estrogen-lowering therapy. The high-dose regimen had significant side effects, while the low-dose regimen was well tolerated.
Researchers are studying new treatments, including zoledronic acid, aromatase inhibitors and monoclonal antibodies, with encouraging results. Exemestane has been shown to be more effective in postmenopausal women than current treatment with tamoxifen.
A recent study led by Massachusetts General Hospital researchers found that hormone therapy for prostate cancer does not appear to increase the risk of death from cardiovascular disease. However, other adverse effects such as diabetes and heart disease still exist, necessitating careful treatment strategies.
SLU researchers found a way to get a promising treatment for Alzheimer's and stroke into the brain, reversing symptoms. They discovered a unique approach to delivering drugs past the blood-brain barrier, which had blocked treatments in the past.
Chronic kidney disease exacts a significant toll on women's sexuality and gynecologic health, with hormonal changes affecting body functions. Experts will explore the impact of CKD on women's sexual life cycle, fertility, and pregnancy from adolescence through menopause.
A study published in the New England Journal of Medicine found that testosterone administered by a skin patch improves sexual well-being in post-menopausal women. The research involved over 800 participants from across the globe and suggests testosterone as a potential treatment for low libido in this demographic.
Researchers at Baylor College of Medicine have developed a new high throughput microscopy technique that enables analysis of hormone receptors on a cell-by-cell basis. This allows for personalized medicine applications, such as identifying the most effective drug treatments for mutated cells.
SmartCells' SmartInsulin is a once-a-day, glucose-regulated insulin that maintains continuous blood glucose control while reducing hypoglycemia risk. JDRF's $1M funding supports preclinical safety and efficacy testing for this treatment, aiming to improve patient safety and quality of life.
A team of researchers has discovered a mechanism for the rapid growth of infantile hemangioma, a common childhood tumor. The study found that endothelial cells, which line the blood vessels, are responsible for the tumors' growth and can be targeted with anti-VEGF therapy.
Breast cancer cells can recycle their components to survive antiestrogen therapy, with macroautophagy playing a key role in this survival strategy. Researchers now believe targeting the autophagosome function could significantly improve hormonal treatment for estrogen-positive breast cancer.
A large Danish observational study found that women taking hormone replacement therapy (HRT) who used it on a cyclical basis, through skin or vaginal application, had a reduced risk of heart attacks. This contradicts previous research and suggests that certain HRT regimens may be safer than others.
Researchers found that older men with high-risk prostate cancer who received hormone therapy lived longer and experienced fewer PSA increases compared to those without treatment. A longer duration of hormone therapy resulted in improved overall survival rates, especially among those over 70.
A large cohort study found that hormone therapy before radiation seed implants for prostate cancer increases the risk of death by 20% in men over 70 years old with early-stage cancer. This treatment approach may have negative effects on survival, particularly for older patients.